SELLAS is at a rare juncture: a Phase 3 survival trial sitting two deaths from its final analysis, and an
executive-compensation filing that a large part of the retail market read as merger preparation. Both are
knowable from primary documents. This page states exactly what has been filed and disclosed: the
REGAL event mechanics, the full text and terms of the June 24 2026 amendment, whether such amendments have
historically preceded buyouts, and how the stock has actually reacted to every dated catalyst. There are no
forecasts, price targets, or recommendations anywhere on this page.
REGAL events (deaths)
78 / 80
as of May 11, 2026 · 127d ago
80th event announced?
Not yet
company says it will announce it
Cash & equivalents
$138.3M
Jun 30, 2026 (Q2 10-Q; was $71.8M at YE2025) · $150M ATM unused
SLS daily closes, Oct 2024 to Sep 2026 (Polygon, split-adjusted). Gold markers = REGAL
milestone disclosures. Green marker = the June 24 2026 executive change-of-control amendment. Hover any marker for the date and close.
Latest activity
Every SEC filing and company press release, newest first, with executive quotes taken verbatim from the source document. Updated daily. Nothing here is a third-party report: each item links to the filing or the release it came from.
“Pancreatic cancer remains one of the most difficult solid tumors to treat, with a significant need for new therapeutic approaches,”
Angelos Stergiou, President and Chief Executive Officer
“These studies are designed to deepen our understanding of the mechanistic and translational rationale for CDK9 inhibition in pancreatic cancer. The presentations will explore the potential for SLS009 to create synthetic lethal interactions through rational combinations with BET- and KRAS-directed approaches, as well as its potential to exploit MYC-associated vulnerabilities. We look forward to sha...”
“The first quarter of 2026 marked an important period for SELLAS as we continued to execute across our clinical programs while preparing for the anticipated pivotal Phase 3 REGAL trial data readout,”
Angelos Stergiou, President and Chief Executive Officer
Plus 19 routine filing(s) in this period (Form 4, S-8, 13G and similar). See the full list on EDGAR.
Sources: SEC EDGAR (CIK 1390478) and the SELLAS investor newsroom. Last collected 2026-09-15.
1. The 80th event: what it is and where it stands
REGAL (NCT04229979) is a Phase 3, randomized,
open-label registrational trial of galinpepimut-S (GPS) as maintenance therapy in adults with AML in second
complete remission (CR2) after second-line salvage, who are ineligible for allogeneic stem-cell transplant.
Patients are randomized 1:1 to GPS versus investigator's choice of best available therapy, and the
primary endpoint is overall survival.
Because the endpoint is survival, the trial is event-driven, not calendar-driven: the statistical
analysis plan triggers the final analysis only once 80 events (deaths) have occurred across both arms
pooled. Per the company's May 12, 2026 disclosure, reaching the 80th event triggers, in order: database lock
→ blinded data review → statistical analysis → unblinding → disclosure of topline results.
Two facts govern how the running count should be read. SELLAS states it remains blinded to all
efficacy and survival outcomes, so the disclosed counts are pooled totals that cannot distinguish the GPS arm
from the control arm. And the company stated that because no outcomes analyses were performed, the one-time
aggregate update incurred no statistical penalty.
Measured pace of event accrual
Interval
Days
Events
Days per event
Dec 10, 2024 (60) → Dec 26, 2025 (72)
381
12
31.8
Dec 26, 2025 (72) → May 11, 2026 (78)
136
6
22.7
Overall: 60 → 78
517
18
28.7
Applying each observed pace to the 2 remaining events from the 78-event as-of date
(May 11, 2026) implies arrival around Jun 25, Jul 7 and Jul 14, 2026 respectively. As of
Sep 15, 2026, 127 days after that as-of date: the 80th event has not been announced. This is
arithmetic on company-disclosed counts, not a projection model.
Context in the company's own words. After the IDMC's August 2025 recommendation, the 80th event had been
expected before year-end 2025; it did not occur. In the December 29, 2025 release CEO Angelos Stergiou stated
that survival times "appear longer than expected," and REGAL steering-committee member Dr. Yair Levy stated that
for non-transplant patients in this setting standard treatment carries "an expected median overall survival of
around eight months."
2. The June 24, 2026 amendment: what it actually says
On June 25, 2026 SELLAS shares rose roughly 15% and hit a 52-week high, on volume near double the 65-day
average. Widely-read coverage attributed the move substantially to a Form 8-K filed that week amending
executive severance terms, which was interpreted as preparation for a sale. Here is the filing itself.
The 8-K was filed under Item 5.02(e): Compensatory Arrangements of Certain Officers, covering three
agreements: an amendment to CEO Dr. Angelos Stergiou's employment agreement, and amended-and-restated severance
and change-of-control letter agreements with CFO John Burns and Chief Development Officer Dr. Dragan Cicic.
"The Agreements were approved by the Board of Directors… upon recommendation of the
Compensation Committee of the Board, following a review with the Company's independent compensation
consulting firm of certain market and competitive practices relating to executive severance agreements."
, SELLAS Form 8-K, filed June 24, 2026 (Item 5.02(e))
The actual terms
CEO (Stergiou): what changedOnly that certain change-of-control severance payments are paid as a lump sum
CEO: everything else"The terms… remain unchanged in all other respects"
CFO/CDO: CoC severanceLump sum = 15 months base salary; lump sum = target bonus; 18 months COBRA; full acceleration of unvested equity
Change-of-Control Period1 month before → 12 months after a change of control
Trigger structureDOUBLE trigger: requires a change of control AND termination without Cause / resignation for Good Reason
Conditioned onEffective separation and general release agreement
Five things the filing shows that the popular reading skipped
Read as
"They're locking in golden parachutes because a buyer is at the table."
What the document says
The benefits are double-trigger: a change of control alone pays nothing. An
executive must also be terminated without Cause or resign for Good Reason inside the window. Single-trigger
(vesting on the deal alone) is the structure that pays out on simply completing a sale. Double-trigger is also
the majority market structure, not an unusual one: Meridian Compensation Partners' 2023 study of
change-in-control severance arrangements found 91% of companies vest time-based equity on a double trigger
: i.e. a qualifying termination following a change of control. SELLAS adopted the prevailing structure.
Read as
"A sudden, unexplained restructuring of executive contracts."
What the document says
The filing states its own rationale: Compensation Committee recommendation to the
Board, following review with an independent compensation consulting firm of market and competitive practices.
That is the standard description of routine benchmarking, and it is stated on the face of the filing.
Read as
"Massive payouts were added."
What the document says
The change-of-control cash benefit for the CFO and CDO is 15 months of
base salary (1.25×) plus target bonus, with COBRA for up to 18 months. For scale, Meridian's 2023 study
found a 3× cash multiple is the plurality practice for CEOs (47%), with 2× also common. We note
explicitly that this is not a like-for-like comparison: that benchmark is for chief executives, while
the 15-month figure here applies to a CFO and a CDO, and non-CEO officers customarily carry lower multiples than
the CEO. The defensible statement is the narrow one: these are the disclosed terms, and they are cash multiples
of roughly one year's salary rather than multi-year packages.
Read as
"The CEO's package was overhauled."
What the document says
For the CEO the only change is the form of payment: certain
change-of-control severance is now paid as a lump sum rather than over time. The filing states the agreement is
otherwise unchanged. Converting instalments to a lump sum is a common administrative/tax-timing change.
Read as
"This is a merger-related filing."
What the document says
On the 8-K cover page, the boxes for written communications under Rule 425,
soliciting material under Rule 14a-12, and pre-commencement tender-offer communications under Rules 14d-2(b)
and 13e-4(c) are all unchecked. Those are the boxes a filer checks when a communication relates to a
merger or tender offer.
None of the above establishes that a transaction is not occurring. Companies do amend
compensation ahead of deals, and boards are not required to disclose negotiations. It establishes only what this
particular document does and does not say, and this document describes benchmarking with a double-trigger structure.
3. Has this pattern historically preceded a buyout?
The inference "change-of-control amendment → imminent acquisition" is testable. We searched SEC EDGAR
full-text for 8-K filings containing comparable change-of-control severance language over the trailing 12 months
(Aug 1, 2025 to Aug 1, 2026, a fixed 12-month window, not a rolling one), kept filers in pharma/biotech SIC codes (2834, 2836, 8731), deduplicated to one
row per company, and then checked whether each ticker still trades independently today.
Company
Ticker
Comparable CoC 8-K filed
Status as of Sep 15, 2026
Ardelyx, Inc.
ARDX
2025-08-04
Still trading independently
Stoke Therapeutics, Inc.
STOK
2025-10-06
Still trading independently
Xenon Pharmaceuticals Inc.
XENE
2025-12-01
Still trading independently
Imunon, Inc.
IMNN
2026-05-04
Still trading independently
SELLAS Life Sciences Group, Inc.
SLS
2026-06-25
Still trading independently
Result: of the 5 comparable biotech/pharma filers identified in the window,
0 have been acquired or taken private as of Sep 15, 2026.
Stated limits of this measurement. EDGAR full-text search matches exact phrases in the filing
body, and many companies describe these arrangements in other words or incorporate them by reference to an exhibit;
this search therefore undercounts the true population, and 5 is a small sample rather than a census. The
"still trading" check is also a proxy; a ticker can stop quoting for reasons other than acquisition
(bankruptcy, reverse merger, ticker change, delisting). Treat this as a directional check on a popular inference,
not a precise base rate. Readers can reproduce it: the filings are public and the tickers are named above.
The academic literature addresses a related but distinct question. Studies of golden parachutes find that
firms whose executives hold such arrangements are associated with a greater likelihood of acquisition and a
lower acquisition premium, and that adoption is generally received as a negative event, more so for more
generous agreements. Note the distinction that matters here: that research concerns having change-of-control
protection, not amending its payment mechanics, and it describes population-level associations rather than
a signal about any single company.
4. Every dated catalyst and its measured stock reaction
Day-of move is the close on the first trading day on or after the announcement versus the prior close; +5d is
five sessions later versus that same prior close. Computed from Polygon split-adjusted daily closes. The full
21-event table, including volume multiples, is in the companion study.
Across 21 dated events since Nov 2024, the mean absolute day-of move was 6.1%; only 8 of 21 (38%) closed higher on the day.
Mean signed day-of move was −1.1%, while the mean move five sessions later was +9.5%; the drift after these events was consistently larger and more positive than the day-of reaction.
The two most positive-sounding REGAL headlines were sold on the day: the 60th-event interim-analysis trigger (Dec 10, 2024) closed −4.6% and fell a further 17.8% the next session; the positive interim-analysis outcome (Jan 23, 2025) closed −13.3% on 17.4× average volume: then was +16.7% five sessions later.
The Dec 29, 2025 release disclosing that the 80th event had not arrived on schedule closed +16.7% on 4.3× volume, and was +42.9% five sessions later.
REGAL/IDMC events (n=5) averaged a 7.2% absolute day-of move and +16.5% at +5d; SLS009 and conference-data events (n=9) averaged 4.0% day-of and +3.1% at +5d.
Both columns contain only statements traceable to a primary source or computed from market data, presented
without weighting. Neither column is a recommendation.
Cited by the bull case
The pre-specified 60-event interim analysis was passed (futility, efficacy, safety): announced Jan 23, 2025.
At that analysis, pooled median survival appeared to be at least 13.5 months against an expected ~6 months in a comparable population.
The IDMC recommended continuation without modification in August 2025, with no safety concerns identified.
Event accrual has run slower than projected, which the company attributes to survival times appearing longer than expected (pooled, blinded).
FDA and EMA orphan drug designation for GPS in AML, plus FDA Fast Track in AML.
$138.3M cash at Jun 30, 2026 (Q2 10-Q), up from $71.8M at year-end 2025; no debt disclosed. The 10-Q states cash is expected to fund planned operations for at least the next twelve months from its issuance.
The cash came from warrant holders, not a new offering: $82.9M received in H1 2026 from the exercise of 48.8M warrants at a weighted-average $1.70 per share (Q2 10-Q). Only 9.7M warrants remained outstanding at Jun 30.
A $150M ATM is established and entirely unused; the Q2 10-Q states the company has not sold any shares through it to date.
Q2 2026 R&D rose to $6.3M from $3.9M ($11.4M vs $7.1M for the half), attributed primarily to manufacturing, regulatory consulting and trial costs in preparation for a potential BLA for GPS following the final analysis.
The Greater China licence survives the arbitration. Per the Jul 27, 2026 8-K, 3D Medicines said it will continue developing GPS in its territory under the exclusive licence, under which $191.5M in potential future milestone payments remained as of Mar 31, 2026.
SLS009 at ASH 2025: 46% ORR across cohorts, 58% in patients with one prior line, median OS 8.9 months in the least pre-treated cohort vs a stated ~2.5-month historical benchmark.
A second, independent catalyst: Phase 2 of SLS009 in newly diagnosed first-line AML, topline expected Q4 2026 (28 patients enrolled per the Aug 11, 2026 8-K).
Cited by the bear case
The timeline has slipped repeatedly. The 80th event was expected before year-end 2025; as of Sep 15, 2026 it is unannounced, 127 days past the 78-event as-of date and beyond all three windows implied by the company's own disclosed pace.
Blinded pooled counts cannot distinguish the arms. Longer pooled survival could reflect the control arm, the GPS arm, or both; SELLAS is blinded and cannot say.
REGAL is open-label, a 1:1 randomized comparison against investigator's choice, not a blinded placebo-controlled design.
Share count roughly doubled year over year: weighted-average shares 98.6M (Q2 2025) to 189.2M (Q2 2026); shares outstanding 153.1M at Dec 31, 2025 to 201.9M at Jun 30, 2026, mostly from warrant exercises (Q2 10-Q).
The unused $150M ATM represents authorized future dilution on top of that increase, and 35.3M further shares are reserved for warrants, options, RSUs and plan issuance.
Losses are widening: net loss $9.6M in Q2 2026 vs $6.6M in Q2 2025 ($18.0M vs $12.4M for the half); accumulated deficit $293.0M at Jun 30, 2026.
The 3D Medicines arbitration was lost. On Jul 24, 2026 the sole HKIAC arbitrator dismissed SELLAS's claims (which sought, among other things, $13.0M of disputed milestone payments) and allocated roughly $1.0M of 3D Medicines' legal and administrative costs to SELLAS, taken as a Q2 charge (Jul 27, 2026 8-K; Q2 10-Q note 5).
The interim analysis was a continuation decision, not a success declaration: it permitted the trial to continue; it did not establish the primary endpoint will be met.
Positive REGAL headlines have historically been sold (see the reaction record above).
Part of the mid-2026 move was not clinical, coverage attributed the June 25 surge substantially to the change-of-control amendment being read as merger preparation, and to retail/WallStreetBets momentum.
Expectations are elevated: the stock closed at $11.29 on 2026-09-15 against a 52-week range of $1.39: $15.46, having risen roughly 572% over the trailing year.
Program reference
Lead assetGalinpepimut-S (GPS): WT1-targeting immunotherapeutic
GPS originLicensed from Memorial Sloan Kettering Cancer Center
Pivotal trialREGAL, Phase 3, NCT04229979
PopulationAML in CR2/CRp2 after second-line salvage, transplant-ineligible
Design / endpoint1:1 randomized, open-label, GPS vs best available therapy / overall survival
Final-analysis trigger80 events (deaths), pooled across arms
Second assetSLS009 (tambiciclib): selective CDK9 inhibitor
SLS009 next catalystPhase 2 first-line AML topline expected Q4 2026 (28 enrolled, Aug 11 8-K)
SLS009 conferenceThree PRECLINICAL posters (PDAC, with Univ. of Wisconsin) at the AACR Conference on Pancreatic Cancer, Sep 25 to 28, 2026, San Diego. Preclinical data, not a clinical readout; the clinical-readout conference statistics on this site do not apply to it.
SEC Form 8-K, filed July 27, 2026 (Items 2.02, 8.01): the HKIAC arbitrator's July 24 decision dismissing SELLAS's claims against 3D Medicines, ~$1.0M of costs allocated to SELLAS, and 3D Medicines' statement that GPS development in Greater China continues under the licence ($191.5M potential milestones remaining as of Mar 31, 2026).
Stock-reaction figures are computed by pdufa.bio from Polygon split-adjusted daily closes; daily closes
understate intraday ranges. Where an announcement fell on a non-trading day, the first following session is used.
Page compiled 2026-09-15 and updated as new filings are published.
Common questions
When is the next FDA decision or readout for SELLAS Life Sciences (SLS)?
Q4 2026. SELLAS Life Sciences has 2 catalysts guided to that date: SLS009 (tambiciclib) Phase 2 AML readout; REGAL Phase 3 (galinpepimut-S) topline, event-driven (readout). That date is known to the quarter only. Dates are taken from FDA notices, company filings or ClinicalTrials.gov, and we do not publish a specific day when the source only gives a month or a quarter.
How do stocks like SLS move into an FDA decision?
We have no measured history for SLS itself. Across the whole study of 1,849 FDA decisions, the median stock rose 17.9% at its best point in the 120 trading days before the decision, but was only 2.1% higher the day before it. Most of the move happened before the answer arrived and was largely given back.
Where does this SLS data come from?
FDA publications, company filings with the SEC, company press releases and ClinicalTrials.gov, with share prices measured from daily closing data. Every date and outcome links the document it came from. Where an outcome was inferred from the price reaction rather than read from a filing, the page says so on its face.
Not affiliated with or endorsed by the FDA, SELLAS Life Sciences, or any company mentioned. pdufa.bio is an independent publication with no affiliation with, endorsement by, sponsorship by, or connection to the U.S. Food and Drug Administration or any other government agency. “FDA”, “PDUFA” and all company, drug and ticker names are used descriptively and remain the property of their respective owners.
Informational and educational purposes only. Not investment advice. Nothing on this page is investment, legal, tax or medical advice, or an offer or solicitation to buy or sell any security. pdufa.bio is not a registered investment adviser or broker-dealer and does not recommend trades or publish individual-drug approval probabilities. pdufa.bio is an independent service. This page contains factual statements, filed document text, and historical price statistics only; it makes no forecast and no recommendation about any security. Event-driven readout timing, interim results and corporate transactions are inherently uncertain. Verify every date and outcome against primary FDA, SEC or company filings. Data is provided as is, without warranty of any kind, and past behaviour does not predict future outcomes.